ReviewInfection and drug resistance2019
Multiresistant
Review in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Article
- The Multifaceted Menace ofBiology · 2026Review
- Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach.Scientific reports · 2025Article
- Silent invaders: the hidden threat of asymptomatic phytobiomes to forest biosecurity.The New phytologist · 2025Review
- Fungicide resistance in Fusarium species: exploring environmental impacts and sustainable management strategies.Archives of microbiology · 2025Review
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- Biofilm Formation in Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2024Article
- Assessment of Genetic Diversity and the Population Structure of Species from theJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Endophthalmitis as the initial manifestation of invasive fusariosis in an allogeneic stem cell transplant patient: A case report.Medical mycology case reports · 2023Article
- Prospecting Plant Extracts and Bioactive Molecules with Antimicrobial Activity in Brazilian Biomes: A Review.Antibiotics (Basel, Switzerland) · 2023Review
- Microbial diversity in soils suppressive toFrontiers in plant science · 2023Review
- Antifungal activity of a novel synthetic polymer M451 against phytopathogens.Frontiers in microbiology · 2023Article
- Species Diversity in the Fusarium solani (Neocosmospora) Complex and Their Pathogenicity for Plants and Humans.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2022Article
- In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Ten decadal advances in fungal biology leading towards human well-being.Fungal diversity · 2022Review
- Fungal Genomics in Respiratory Medicine: What, How and When?Mycopathologia · 2021Review
- Investigational Agents for the Treatment of Resistant Yeasts and Molds.Current fungal infection reports · 2021Review
- Discovery of a Novel LineageInternational journal of microbiology · 2021Article
- A One Health Perspective to RecognizeJournal of fungi (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fungal genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.